Competing interests
J.W.T. has been an advisory board member for Lumos, Pfizer AstraZeneca and Poxel. R.R.H. reports research support from AstraZeneca, Bayer and Merck Sharp & Dohme, and personal fees from Anji Pharmaceuticals, Novartis and Novo Nordisk. A.M.I. received consultation fees, unconditional grants and hospitality to conferences from IBSA, Takeda and IPSEN. R.E. receives consultancy funding from Immunodiagnostic Systems, Sandoz, Samsung, Haoma Medica, CL Bio, Biocon, Coherus, Takeda, meeting presentations for Pharmacosmos, Alexion and Amgen, and grant funding from Roche, Pharmacosmos and Alexion. A.W., K.J.E. and U.K. are full-time employees of AstraZeneca. The work has been supported by the NIHR Oxford Biomedical Research Centre. The remaining authors declare no other competing interests.